SKYRIZI (Abbvie Pty Ltd)
Product name
SKYRIZI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
risankizumab
Registration type
EOI
Indication
SKYRIZI (solution for injection) is now also indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
SKYRIZI may be used with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).